John Martin Net Worth

The estimated Net Worth of John C Martin is at least $265 Миллион dollars as of 14 October 2020. John Martin owns over 75,800 units of Sarepta Therapeutics Inc stock worth over $250,664,014 and over the last 21 years he sold SRPT stock worth over $14,010,011. In addition, he makes $0 as Independent Director at Sarepta Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Martin SRPT stock SEC Form 4 insiders trading

John has made over 132 trades of the Sarepta Therapeutics Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 75,800 units of SRPT stock worth $1,440,200 on 14 October 2020.

The largest trade he's ever made was exercising 282,242 units of Sarepta Therapeutics Inc stock on 2 December 2013 worth over $2,153,506. On average, John trades about 72,300 units every 31 days since 2003. As of 14 October 2020 he still owns at least 1,952,364 units of Sarepta Therapeutics Inc stock.

You can see the complete history of John Martin stock trades at the bottom of the page.

John Martin biography

Dr. John C. Martin Ph.D. serves as Independent Director of the Company. Dr. Martin served as the Executive Chairman and Chairman of Gilead Sciences, Inc., from March 2016 through March 2019, after having served as Chairman and Chief Executive Officer from June 2008 through March 2016 and President and Chief Executive Officer from 1996 through May 2008. He joined Gilead in 1990 as Vice President, Research and Development. Prior to Gilead, Dr. Martin held several leadership positions at Bristol-Myers Squibb and Syntex Corporation. Martin currently serves on the Board of Directors at The Scripps Research Institute and Kronos Bio. Additionally, he served on the Centers for Disease Control/Health Resources and Services Administration's Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS. In 2008, Dr. Martin was inducted into the National Academy of Engineering and, in 2019, he received the National Academy of Sciences Award for Chemistry in Service to Society. Dr. Martin holds a Ph.D. in organic chemistry from the University of Chicago, an MBA from Golden Gate University and a B.S. degree in chemical engineering from Purdue University.

How old is John Martin?

John Martin is 67, he's been the Independent Director of Sarepta Therapeutics Inc since 2020. There are 1 older and 13 younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.

What's John Martin's mailing address?

John's mailing address filed with the SEC is 215 FIRST STREET, SUITE 415, , CAMBRIDGE, MA, 02142.

Insiders trading at Sarepta Therapeutics Inc

Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry и M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.

What does Sarepta Therapeutics Inc do?

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.

Complete history of John Martin stock trades at Gilead Sciences, Sarepta Therapeutics Inc и Kronos Bio

Sarepta Therapeutics Inc executives and stock owners

Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include:

• Gilmore O'Neill,
  Executive Vice President, R&D and Chief Medical Officer
• William Ciambrone,
  Executive Vice President - Technical Operations
• David Howton,
  Executive Vice President, General Counsel, Secretary
• Alexander Cumbo,
  Executive Vice President and Chief Commercial Officer
• Douglas Ingram,
  President, Chief Executive Officer, Director
• Douglas S. Ingram,
  Pres, CEO & Director
• Dr. Gilmore O'Neill M.D.,
  Exec. Officer
• Dr. Louise Rodino-Klapac Ph.D.,
  Chief Scientific Officer and Head of R&D
• Ian Michael Estepan,
  Exec. VP & CFO
• William F. Ciambrone,
  Exec. VP of Technical Operations
• M. Kathleen Behrens,
  Independent Chairwoman of the Board
• Richard Barry,
  Independent Director
• Hans Wigzell,
  Independent Director
• Claude Nicaise,
  Independent Director
• Mary Gray,
  Independent Director
• John Martin,
  Independent Director
• Joseph Bratica,
  Interim Principal Financial and Accounting Officer
• Dr. Diane L. Berry,
  Sr. VP of Global Health Policy and Gov. & Patient Affairs
• Alison Nasisi,
  Chief People Officer & VP
• Ryan E. Brown,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Mary Jenkins,
  Sr. Mang. of Investor Relations
• Michael W Bonney,
  Director
• Ben Gil Price,
  Director
• Catherine Stehman Breen,
  SVP, Chief Medical Officer
• Jayant Aphale,
  SVP Technical Operations
• Jean Paul Kress,
  Director
• William Alden Goolsbee,
  Director
• Shamim Ruff,
  SVP, Chief Regulatory Affairs
• Sandesh Mahatme,
  EVP, CFO & CBO
• Guriqbal S. Basi,
  SVP, Chief Scientific Officer
• Michael A Jacobsen,
  VP of Finance and PAO
• Anthony Martignetti,
  
• Nishan Garabedian Christopher,
  President and CEO
• Anthony R Chase,
  Director
• John Hodgman,
  Director
• Arthur M Krieg,
  SVP, Chief Scientific Officer
• Edward M. Md Kaye,
  SVP & Chief Medical Officer
• Ian Michael Estepan,
  Chief Financial Officer
• Ryan Edward Brown,
  EVP, General Counsel
• Louise Rodino Klapac,
  Head of R&D, CSO
• Bilal Arif,
  Chief Tech Ops Officer
• Stephen Mayo,
  
• Kathryn Jean Boor,
  
• Dallan Murray,
  Chief Customer Officer